Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors

Table 2 Clinical and demographic variables and risk of AAIA

Characteristic	Reported AIAA (N= 390)		P-value²
	N	%
Educational Level			0.11
High school or less	29	42.0
College or more	169	52.7
Reasons for menopause			0.13
Natural	98	47.6
Induced	91	55.5
Years since LMP			<.001
<5	50	65.8
5 to 10	63	60.6
>10	83	40.7
Body mass index			0.62
<25	97	50.5
25 to 30	68	45.3
>30	68	49.3
Stage			0.991
0 and I	75	50.4
II	102	51.0
III	21	51.2
Chemotherapy			0.006
None	59	41.3
Chemotherapy, but no Taxane	49	50.2
Chemotherapy included Taxane	90	60.0
Aromatase inhibitors			0.62
Letrozole (Femara)	33	46.5
Anastrozole (Arimidex)	119	49.4
Exemestane (Aromasin)	24	55.8
Years since start of AI ¹			0.02
<1	56	49.1
1 to 3	67	59.6
>3	55	41.7
Estrogen levels
Detectable estradiol	74	47.4	0.84
Detectable estrone	134	85.9	0.73

Abbreviations: AIAA, Aromatase Inhibitor associated Arthralgia; LMP, last menstrual period.
¹Among those who are currently on AIs.
²Chi-square.

ISSN: 1465-542X